TrialSignal transduction and targeted therapy2026
Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.
Bo Lan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.